


## Assessment of value for oncology products is becoming more complex as most products have multiple indications

### Near-launch Oncology Pipeline Assets and Target Indications



- Of 88 cancer drugs marketed in 2014, 40 were for single indications and 48 for multiple indications.
- Currently, several of the single indication drugs are in clinical trials for Phase 2 and above and if approved, will be available to treat other indications.
- By 2020, most oncology drugs will carry multiple indications, reflecting developers' pursuit of genetic targets across multiple tumors, and the rise of immuno- oncologics, which may have more than six indications.

Chart notes:

It includes compounds from Ph II to registration. It does not account for failures